Am Fam Physician. 2014 Jan 15;89(2):131.
Does metformin (Glucophage) affect cardiovascular events in patients with type 2 diabetes mellitus?
Over five years, treatment with metformin for three years, with other hypoglycemics as needed, reduced the likelihood of death, nonfatal stroke, or the need for vascularization compared with treatment beginning with glipizide (Glucotrol). Cardiovascular events were not individually reduced with metformin compared with glipizide. (Level of Evidence = 1b–)
These authors enrolled patients with type 2 diabetes and coronary artery disease, and followed them for a median of five years. The average age of all 304 patients was 63.3 years; 77% were men. After stopping current treatment (which included insulin in approximately 10% of the group), patients were randomized, with allocation concealment unknown, to receive 30 mg of glipizide daily or 1,500 mg of metformin daily, with additional treatment added as needed, to achieve an average A1C level of 7%. In each group, 25% of patients ended up receiving insulin in addition to the study drug. Using intention-to-treat analysis, the investigators compared the incidence of recurrent cardiovascular events in the two groups, including death, nonfatal stroke, or need for revascularization. After a median follow-up of five years, one or more events occurred in 35% of patients treated with glipizide and in 25% of patients treated with metformin (adjusted hazard ratio = 0.54; P = .026), which translates to a number needed to treat of 9.4 for five years. Death rates were not different between the two groups. This small study reinforces the findings from the long-ago study (Diabetes. 1970;19:747–830) that resulted in U.S. Food and Drug Administration warnings of an increased risk of cardiovascular events with sulfonylurea hypoglycemics.
Study design: Randomized controlled trial (double-blinded)
Funding source: Government
Setting: Outpatient (any)
Reference: Hong J, Zhang Y, Lai S, et al.; SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care.. 2013; 36( 5): 1304– 1311.
POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Aug 1, 2016
Access the latest issue of American Family Physician